America's Best Nonprofits
  1. Home
  2. Medical Research
  3. Rockville, MD
  4. Biohealth Innovation

Biohealth Innovation

Biohealth Innovation is ranked #7 of 8 medical research organizations in Rockville, MD, with an America's Best Score of 69 out of 100, based on its 2025 Form 990.

  • Rockville, MD
  • Tax-exempt since 2012
  • EIN: 45-3824067
biohealthinnovation.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
69OF 100 #7 of 8 in Rockville ranked medical research organizations How this score is calculated

Organization summary

Biohealth Innovation is a 501(c)(3) organization, classified under Medical Research (NTEE H02). Contributions are tax-deductible.

1 Church St Ste 801, Rockville, MD 20850-5129

Among the 11 scored medical research organizations in Rockville, Biohealth Innovation holds 14 months of operating reserves (peer median 11.8 months), runs a typical yearly surplus of 2.4% (peers: surplus of 2.4%), and has grown spending 4.7% a year (peers: grown spending 4.7% a year).

In fiscal year 2025 it reported $4,160,141 in revenue and $4,229,165 in expenses, with contributions making up 88.2% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

Biohealth Innovation connects market relevant research assets to appropriate funding, management, and markets to facilitate the development of commercially viable bio health products and companies.

Main program · fiscal year 2025

  • Entrepreneur-in-Residence/Small Business Innovative Research (SBIR): The BHI SBIR/STTR federal funding assistance offers BioHealth companies support in preparing applications for federal funding inclusive of SBIRS, STTRS, and other federal government awards. BHI's Entrepreneur-in-Residence (EIR) program is designed to be an active partner with research institutions to source, fund, and grow high-p… Read more

    Entrepreneur-in-Residence/Small Business Innovative Research (SBIR): The BHI SBIR/STTR federal funding assistance offers BioHealth companies support in preparing applications for federal funding inclusive of SBIRS, STTRS, and other federal government awards. BHI's Entrepreneur-in-Residence (EIR) program is designed to be an active partner with research institutions to source, fund, and grow high-potential, early-stage products through project-focused companies. The entrepreneurs in the program support the formation of new companies based upon innovative discoveries in the areas of drugs, vaccines, therapeutics, diagnostics, and medical devices from the intramural research programs at partner organizations, as well as from universities and businesses. The EIR will find, evaluate, and support the development of new start-up companies based upon technology license agreements from technology transfer offices or equivalent units within the research institutions. Under an NIH/OTT partnership intermediary agreement, BHI will employ and place entrepreneurs-in-residence (EIR) within OTT to evaluate, identify and license intramural technologies in the areas of drugs, vaccines, therapeutics, diagnostics and medical devices from the intramural research programs at both the NIH and the Food and Drug Administration (FDA). An NIH EIR is an industry expert with scientific, entrepreneurial/managerial and financial experience who works side by side with NIH scientists to identify, evaluate and support the development of new start-up companies based upon technology license agreements from OTT. The innovate UMBC program provides applied training for post-doctoral fellows, research scientists, and other professionals who want to start life science-based companies. The program was launched in 2010 with a 3-year funding grant from the National Science Foundation (NSF). The university of Maryland, Baltimore County (UMBC) will offer the program at the universities at shady grove's campus in Montgomery County, Maryland. The program is intended for scientists interested in commercializing biomedical technology. Partners in the program are biohealth innovation, inc. And the Montgomery County department of economic development.

    $3,384,707 spent

Where each dollar went · fiscal year 2025

Of every dollar it spent, 80¢ went to programs, 9¢ to management and 11¢ to fundraising.

  • Programs $3,384,707
  • Management $388,846
  • Fundraising $455,612

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score69 / 100
Rank in Rockville#7 of 8
DesignationRanked

Score breakdown

MeasureThis organizationPoints
Operating reserves14.0 mo; 1.6 mo in cash9.7 / 25
Financial balance (median margin)+2.4%14 / 20
Transparency4 full 990s, latest TY202520 / 20
Program growth+4.7% / yr9.8 / 15
Track record14 years5.6 / 10
Debt load8.3% of assets10 / 10
Total69.1 → 69
Spending on programs
Not scored; America's Best needs 65%+
80%Meets

Compared with Rockville peers

MeasureThis organizationPeer median
Operating reserves14.0 mo11.8 mo
Typical margin+2.4%+2.4%
Spending growth+4.7% / yr+4.7% / yr
Debt load8.3%10.6%

Peers: the 11 Rockville medical research organizations with a score, ranked or below the bar.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$4,160,141Fiscal year 20252022: $4,065,00620222023: $4,643,95220232024: $4,436,12320242025: $4,160,1412025
Expenses$4,229,165Fiscal year 20252022: $3,686,77320222023: $4,364,94820232024: $4,740,87620242025: $4,229,1652025
Total assets$5,378,772Fiscal year 20252022: $5,438,81220222023: $5,807,11320232024: $5,288,05020242025: $5,378,7722025
Total liabilities$447,170Fiscal year 20252022: $344,87720222023: $433,05220232024: $287,42420242025: $447,1702025
Fiscal year ending December 2025
Revenue$4,160,141
Expenses$4,229,165
Net income−$69,024
Net assets$4,931,602

Notable sources of revenue

Percent of total revenue
Contributions$3,667,346
Program services$477,203
Investment income$15,592
Other (net)$0

Assets / debt

Total assets$5,378,772
Total liabilities$447,170
Net assets$4,931,602

Compensation

Not in our extract for this year.

Fiscal year ending December 2024
Revenue$4,436,123
Expenses$4,740,876
Net income−$304,753
Net assets$5,000,626

Notable sources of revenue

Percent of total revenue
Contributions$3,498,516
Program services$917,163
Investment income$20,444
Other (net)$0

Assets / debt

Total assets$5,288,050
Total liabilities$287,424
Net assets$5,000,626

Compensation

Not in our extract for this year.

Fiscal year ending December 2023
Revenue$4,643,952
Expenses$4,364,948
Net income$279,004
Net assets$5,374,061

Notable sources of revenue

Percent of total revenue
Contributions$3,976,654
Program services$667,298
Investment income$0
Other (net)$0

Assets / debt

Total assets$5,807,113
Total liabilities$433,052
Net assets$5,374,061

Compensation

Not in our extract for this year.

Fiscal year ending December 2022
Revenue$4,065,006
Expenses$3,686,773
Net income$378,233
Net assets$5,093,935

Notable sources of revenue

Percent of total revenue
Contributions$3,404,859
Program services$660,147
Investment income$0
Other (net)$0

Assets / debt

Total assets$5,438,812
Total liabilities$344,877
Net assets$5,093,935

Compensation

Officers and key employees$522,326
Share of expenses14.2%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?